Journal of
AIDS and HIV Research

  • Abbreviation: J. AIDS HIV Res.
  • Language: English
  • ISSN: 2141-2359
  • DOI: 10.5897/JAHR
  • Start Year: 2009
  • Published Articles: 302

Case Report

Sustained virological response after only 5 weeks treatment with daclatasvir/pegylated interferon and ribavirin as part of a clinical trial in a cirrhotic human immunodeficiency virus (HIV) - hepatitis C virus (HCV) co-infected patient with liver decompensation during treatment

S. Flanagan*
  • S. Flanagan*
  • Department of Infection and Immunology, Royal London Hospital, England.
  • Search for this author on:
  • Google Scholar
A. Umaipalan
  • A. Umaipalan
  • Department of Infection and Immunology, Royal London Hospital, England.
  • Search for this author on:
  • Google Scholar
G. Baily
  • G. Baily
  • Department of Infection and Immunology, Royal London Hospital, England.
  • Search for this author on:
  • Google Scholar
C. Orkin
  • C. Orkin
  • Department of Infection and Immunology, Royal London Hospital, England.
  • Search for this author on:
  • Google Scholar


  •  Received: 13 January 2015
  •  Accepted: 09 March 2015
  •  Published: 31 March 2015

Abstract

This study presents a case of a sustained virological response to 24 weeks early cessation of hepatitis C direct acting antiviral (DAA) treatment with daclatasvir/peginterferon (PEG-IFN)/ribavirin (RBV), mandated by liver decompensation, in a clinical trial subject with advanced liver disease and human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection.

Key words: Human immunodeficiency virus (HIV), hepatitis C, daclatasvir, liver decompensation, sustained virological response, HIV/hepatitis C co-infection.

Copyright © 2025 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 7 No. 3
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES